Clinical dose findings of sitafloxacin treatment: Pharmacokinetic- pharmacodynamic analysis of two clinical trial results for community-acquired respiratory tract infections

Journal of Infection and Chemotherapy

Volumn 19, Issue 3, 2013, Pages 486-494

  Kohno, Shigeru ^a   Niki, Yoshihito ^b   Kadota, Jun Ichi ^c   Yanagihara, Katsunori ^a   Kaku, Mitsuo ^d   Watanabe, Akira ^e   Aoki, Nobuki ^f   Hori, Seiji ^g   Fujita, Jiro ^h   Tanigawara, Yusuke ⁱ  

^a NAGASAKI UNIVERSITY HOSPITAL   (Japan)

^b SHOWA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c OITA UNIVERSITY   (Japan)

^d TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^e TOHOKU UNIVERSITY   (Japan)

^f Shinrakuen Hospital   (Japan)

^g JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^h UNIVERSITY OF THE RYUKYUS   (Japan)

ⁱ KEIO UNIVERSITY   (Japan)

Author keywords

Fluoroquinolone; Pneumococci; Randomized study

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; C REACTIVE PROTEIN; GAMMA GLUTAMYLTRANSFERASE; SITAFLOXACIN;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHMA; COMMUNICABLE DISEASE; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DISTRIBUTION VOLUME; DOSAGE SCHEDULE COMPARISON; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG SAFETY; EOSINOPHIL COUNT; ERADICATION THERAPY; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; MULTICENTER STUDY; NAUSEA; NEUTROPHIL COUNT; OPEN STUDY; PATHOGEN CLEARANCE; PHARMACODYNAMICS; PNEUMOCOCCAL INFECTION; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT INFECTION; SIDE EFFECT; STREPTOCOCCUS PNEUMONIAE; TREATMENT DURATION;

EID: 84879217406     PISSN: 1341321X     EISSN: 14377780     Source Type: Journal    
DOI: 10.1007/s10156-012-0543-z     Document Type: Article

References (22)

1. Craig WA. Does the dose matter? Clin Infect Dis. 2001;33(suppl 3):S233-7.
2. Saito A, Tanigawara Y, Watanabe A, Aoki N, Niki Y, Kohno S, et al. Open study of sitafloxacin in patients with respiratory tract infections - PK/PD study (in Japanese). Jpn J Chemother. 2008;56(S-1):63-80.
3. Yamaguchi K, Ohno A, Ishii Y, Tateda K, Iwata M, Kanda M, et al. In vitro susceptibilities to levofloxacin and various antibacterial agents of 18,639 clinical isolates obtained from 77 centers in 2004 (in Japanese). Jpn J Antibiot. 2006;59:428-51.
4. Yamaguchi K, Ohno A, Ishii Y, Tateda K, Iwata M, Kanda M, et al. In vitro susceptibilities to levofloxacin and various antibacterial agents of 12,919 clinical isolates obtained from 72 centers in 2007 (in Japanese). Jpn J Antibiot. 2009;62:346-70.
5. Wikler MA, Low DA, Cookerill FR, Sheehan DJ, Craig WA, Tenover FC, et al. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically: approved standard. Seventh edition. CLSI (NCCLS). 2006;26:M7-A7.
6. Blondeau JM, Zhao X, Hansen G, Drlica K. Mutant prevention concentrations of fluoroquinolones for clinical isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother. 2001;45:433-8.
7. Saito A, Miki F, Oizumi K, Rikitomi N, Watanabe A, Koga H, et al. Clinical evaluation methods for new antimicrobial agents to treat respiratory infections: report of the Committee for the Respiratory System, Japan Society of Chemotherapy. J Infect Chemother. 1999;5:110-23.
8. Japanese Society of Chemotherapy. Criteria for assessment of adverse reactions and abnormal laboratory values associated with antimicrobial agents in study subjects (in Japanese). Jpn J Chemother. 1991;39:687-9.
9. Japanese Society of Chemotherapy. About the partial modification of ''Criteria for assessment of adverse reactions and abnormal laboratory values associated with antimicrobial agents in study subjects" (in Japanese). Jpn J Chemother. 1995;43 (opening article).
10. Mouton JW, Dudley MN, Cars O, Derendorf H, Drusano GL. Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs. Int J Antimicrob Agents. 2002;19:355-8.
11. Matsumoto T, Uchino K, Yamaguchi H, et al. Study on the safety and efficacy of sitafloxacin: results of the use-results survey (in Japanese). Jpn J Antibiot. 2011;64:319-37.
12. Hsueh PR. Study for monitoring antimicrobial resistance trends (SMART) in the Asia-Pacific region, 2002-2010. Int J Antimicrob Agents. 2012;40(S1):S1-3.
13. Tiengrim S, Phiboonbanakit D, Thunyaharn S, Tantisiriwat W, Santiwatanakul S, Susaengrat W, et al. Comparative in vitro activity of sitafloxacin against bacteria isolated from Thai patients with urinary tract infections and lower respiratory tract infections. J Med Assoc Thai. 2012;95(S2):S6-17.
14. Yamaguchi K, Ohno A, Ishii Y, Tateda K, Iwata M, Akizawa H, et al. In vitro susceptibilities to levofloxacin and various antibacterial agents of 12,866 clinical isolates obtained from 72 centers in 2010 (in Japanese). Jpn J Antibiot. 2012;65:181-206.
15. Nakashima M, Uematsu T, Kosuge K, Umemura K, Hakusui H, Tanaka M. Pharmacokinetics and tolerance of DU-6859a, a new fluoroquinolone, after single and multiple oral doses in healthy volunteers. Antimicrob Agents Chemother. 1995;39:170-4.
16. Keating GM. Sitafloxacin: in bacterial infections. Drugs. 2011;71(6):731-44.
17. Kawada Y, Ishihara S, Matsui T, Tsugawa M, Matsumoto T, Watanabe K, et al. Comparative study on sitafloxacin and levofloxacin in complicated urinary tract infections (in Japanese). Jpn J Chemother. 2008;56(S-1):81-91.
18. Kawada Y, Yasuda M, Tanaka K, Monden K, Akasaka S, Egashira T, et al. Dose-comparative study of sitafloxacin in complicated urinary tract infections (in Japanese). Jpn J Chemother. 2008;56(S-1):92-102.
19. Baba S, Suzuki K, Yamanaka N, Yamashita H, Kurono Y, Hori S. Efficacy and safety of sitafloxacin in patients with otorhinolaryngological infections and its tissue distribution in the otorhinolaryngological field (in Japanese). Jpn J Chemother. 2008;56(S-1):110-20.
20. Sasaki J, Hori S. Oral tissue distribution, efficacy, and safety of sitafloxacin in patients with dentistry and oral surgery infection (in Japanese). Jpn J Chemother. 2008;56(S-1):121-9.
21. Kawada Y, Matsumoto T, Onodera S, Kaku M, Hori S. Clinical study of sitafloxacin in male nongonococcal urethritis (in Japanese). Jpn J Chemother. 2008;56(S-1):130-8.
22. Matsuda S, Noguchi M, Yasuda J, Hori S. Clinical study of sitafloxacin in treatment of cervicitis with Chlamydia trachomatis (in Japanese). Jpn J Chemother. 2008;56(S-1):139-45.